ArticleBritish journal of pharmacology2020
Effect of selective I
Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- The p.Arg52Leu variant in GNB2 causes a gain-of-function due to an increase of IBMC cardiovascular disorders · 2026Article
- The horse cardiac transcriptome: Moving towards a molecular understanding of atrial fibrillation.Equine veterinary journal · 2026Article
- PKC isoform-specific targeting of the phosphorylation site SerinePflugers Archiv : European journal of physiology · 2026Article
- Metformin Protects Against Persistent Atrial Fibrillation in an Equine Model.Circulation. Arrhythmia and electrophysiology · 2025Article
- Horse model of spontaneous atrial fibrillation share proteomic changes with humans.Scientific reports · 2025Article
- The W101CInternational journal of molecular sciences · 2023Article
- Recent Advances in Antiarrhythmic Drug Therapy.Drugs · 2023Review
- Relevance ofInternational journal of molecular sciences · 2023Review
- Muscarinic acetylcholine receptors MFrontiers in cardiovascular medicine · 2023Article
- Atrial fibrillatory rate as predictor of recurrence of atrial fibrillation in horses treated medically or with electrical cardioversion.Equine veterinary journal · 2022Article
- Distress-Mediated Remodeling of Cardiac Connexin-43 in a Novel Cell Model for Arrhythmogenic Heart Diseases.International journal of molecular sciences · 2022Article
- Electrocardiographic characteristics of trained and untrained standardbred racehorses.Journal of veterinary internal medicine · 2022Article
- Emerging Antiarrhythmic Drugs for Atrial Fibrillation.International journal of molecular sciences · 2022Review
- Pharmacological inhibition of acetylcholine-regulated potassium current (Heart rhythm O2 · 2022Article
- Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review.Diagnostics (Basel, Switzerland) · 2021Review
- Increased fibroblast accumulation in the equine heart following persistent atrial fibrillation.International journal of cardiology. Heart & vasculature · 2021Article
- Comprehensive evaluation of electrophysiological and 3D structural features of human atrial myocardium with insights on atrial fibrillation maintenance mechanisms.Journal of molecular and cellular cardiology · 2021Review
- Kir Channel Molecular Physiology, Pharmacology, and Therapeutic Implications.Handbook of experimental pharmacology · 2021Review
- Inhibition of Small-Conductance Calcium-Activated Potassium Current (Frontiers in physiology · 2021Article
- Effect of selective IBritish journal of pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 5 countries.
Funding
Abstract
background and purposeInhibition of the G-protein gated ACh-activated inward rectifier potassium current, I EXPERIMENTAL APPROACH: The pharmacological ion channel profile of XAF-1407 was investigated using cell lines expressing relevant ion channels. In addition, eleven horses were implanted with implantable cardioverter defibrillators enabling atrial tachypacing into self-sustained AF. The electrophysiological effects of XAF-1407 were investigated after serial cardioversions over a period of 1 month. Cardioversion success, drug-induced changes of atrial tissue refractoriness, and ventricular electrophysiology were assessed at baseline (day 0) and days 3, 5, 11, 17, and 29 after AF induction. KEY
resultsXAF-1407 potently and selectively inhibited K CONCLUSION AND IMPLICATIONS: XAF-1407 efficiently cardioverted sustained tachypacing-induced AF of short duration in horses without notable side effects. This supports I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.